HeartBeam Inc. (NASDAQ: BEAT) announced on July 14, 2026, that it has been granted a patent by the U.S. Patent and Trademark Office for technology that expands its cardiac monitoring platform to include capabilities for heart failure and structural heart disease. The patent, titled 'Method and System for Cardiac Monitoring,' covers a system that uses a wearable device to record cardiac signals and analyze them for signs of these conditions.
According to the company's press release, the patented technology integrates with HeartBeam's existing AIMIGo platform, which provides 12-lead ECG monitoring. The new capabilities aim to detect early indicators of heart failure and structural heart disease, potentially allowing for earlier intervention. HeartBeam CEO Branislav Vajdic stated, 'This patent strengthens our intellectual property portfolio and advances our mission to provide comprehensive cardiac care.'
The patent number is 11,678,123, issued on July 12, 2026. HeartBeam plans to incorporate the technology into future versions of its AIMIGo device, which is currently under development for FDA clearance. The company has not yet announced a timeline for commercial availability.
